Homepage
Catalog of Screening Compounds Screening Libraries Focused and Target Libraries Active Reference Sets Diversity Libraries
Screening Compounds Building blocks
Drug Discovery Services Custom Chemistry Medicinal chemistry In silico Drug Design (CADD) Discovery Biology Animal Models Toxicology and Safety ADME, DMPK Chemistry, Manufacturing and Controls
Company News & Media Contact us For suppliers Trends in discovery compounds
Homepage > Company > Media > Pharma News > 2022

Pharma News, 2022

BMS Bets up to $1.9 Billion on GentiBio’s Treg Platform for Inflammatory bowel disease
BMS Bets up to $1.9 Billion on GentiBio’s Treg Platform for Inflammatory bowel disease

Within the next eight years, more than 3.5 million people in the United States are expected to be diagnosed with inflammatory bowel disease. 

Merck returns to Alzheimer’s disease with $1.1B Cerevance pact
Merck returns to Alzheimer’s disease with $1.1B Cerevance pact

With an investment valued at up to $1.1 billion, Merck is diving back into Alzheimer’s research through a collaboration with Cerevance. 

FDA grants Fast-Track status for Relmada’s major depressive disorder therapy
FDA grants Fast-Track status for Relmada’s major depressive disorder therapy
The US Food and Drug Administration (FDA) has granted Fast-Track designation to Relmada Therapeutics’ REL-1017 as a single agent to treat major depressive disorder (MDD).   ...
FDA Pushed Back PDUFA Date on Omaveloxolone
FDA Pushed Back PDUFA Date on Omaveloxolone
The FDA has pushed back its decision date on Reata Pharmaceuticals’ New Drug Application (NDA) for omaveloxolone, an investigational drug for treatment of the rare inherited neurodegenerative di...
Fresh off Enhertu success, AstraZeneca and Daiichi claim progress for next cancer drug
Fresh off Enhertu success, AstraZeneca and Daiichi claim progress for next cancer drug
A drug combination involving an experimental treatment from AstraZeneca and Daiichi Sankyo has shown early promise in lung cancer, results the two companies believe bolster their recent decision to...
Karuna shares soar on schizophrenia drug results
Karuna shares soar on schizophrenia drug results
Karuna Therapeutics will ask regulators to approved its most advanced drug, an experimental treatment for schizophrenia, now that a large clinical trial has produced results that impressed investor...
Pfizer to Acquire Global Blood Therapeutics for $5.4 Billion to Enhance Presence in Rare Hematology
Pfizer to Acquire Global Blood Therapeutics for $5.4 Billion to Enhance Presence in Rare Hematology
Pfizer Inc. (NYSE: PFE) and Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced the companies have entered into a definitive agreement under which Pfizer will acquire GBT, a biophar...
FDA Lifts Clinical Hold on Celyad Oncology Trial
FDA Lifts Clinical Hold on Celyad Oncology Trial
The FDA has lifted a clinical hold that it placed in March on Celyad Oncology’s early phase clinical trial of CYAD-101, the company’s investigational cell therapy for colorectal cancer. ...
Marius Receives FDA Approval of Kyzatrex for Hypogonadism
Marius Receives FDA Approval of Kyzatrex for Hypogonadism
Marius Pharmaceuticals has received FDA’s approval of its Kyzatrex (testosterone undecanoate) for adult male patients with a deficiency or absence of endogenous testosterone, also known as hypog...
FDA Expands Approval of Bayer’s Nubeqa for Prostate Cancer
FDA Expands Approval of Bayer’s Nubeqa for Prostate Cancer
The FDA has expanded its approval of Bayer’s cancer drug Nubeqa (darolutamide), this time approving the drug in combination with the chemotherapy drug docetaxel for adult patients with metastatic...
Newly discovered chemical reactions may explain the origin of life
Newly discovered chemical reactions may explain the origin of life
Exactly how inanimate molecules came to life is one of science’s most enigmatic mysteries.
Genentech Inks Licensing Deal With Kiniksa Pharmaceuticals
Genentech Inks Licensing Deal With Kiniksa Pharmaceuticals

Genentech has inked a licensing and development deal with Bermuda-based biotech Kiniksa Pharmaceuticals for the company’s investigational drug vixarelimab.

Catalog of Screening Compounds Screening Libraries Screening Compounds Building blocks
Drug Discovery Services News & Media Contact us
Payment systems
Policies & Terms     ©2023 ChemDiv     ChemistryOnDemand